Retirement Systems of Alabama Cuts Holdings in Humana Inc. (NYSE:HUM)

Retirement Systems of Alabama decreased its holdings in Humana Inc. (NYSE:HUM) by 1.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,581 shares of the insurance provider’s stock after selling 395 shares during the period. Retirement Systems of Alabama’s holdings in Humana were worth $9,932,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Mendota Financial Group LLC raised its position in Humana by 9.2% in the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock worth $119,000 after buying an additional 27 shares during the last quarter. Aurora Investment Counsel lifted its position in Humana by 1.3% during the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after purchasing an additional 29 shares during the period. Brighton Jones LLC lifted its position in Humana by 6.8% during the fourth quarter. Brighton Jones LLC now owns 470 shares of the insurance provider’s stock valued at $215,000 after purchasing an additional 30 shares during the period. Merit Financial Group LLC boosted its holdings in Humana by 2.1% in the fourth quarter. Merit Financial Group LLC now owns 1,770 shares of the insurance provider’s stock worth $810,000 after purchasing an additional 37 shares during the last quarter. Finally, EP Wealth Advisors LLC raised its stake in Humana by 1.6% during the 4th quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock valued at $1,050,000 after buying an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

HUM opened at $352.90 on Friday. The stock has a market capitalization of $42.52 billion, a price-to-earnings ratio of 21.97, a PEG ratio of 2.09 and a beta of 0.51. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.67 and a current ratio of 1.66. The company has a fifty day moving average of $367.72 and a 200 day moving average of $346.43.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $8.94 earnings per share. As a group, sell-side analysts forecast that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.00%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio is presently 22.04%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Morgan Stanley began coverage on Humana in a research note on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price target on the stock. TD Cowen boosted their price target on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $395.00 price objective on shares of Humana in a research note on Monday, August 19th. Bank of America boosted their target price on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a research report on Monday, May 20th. Finally, JPMorgan Chase & Co. increased their price target on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday. Thirteen analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $396.35.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.